NCT00333229View on ClinicalTrials.gov

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

PHASE4TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
Interventions
DRUG

Zoledronic Acid

4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.

DRUG

Placebo

Matching Placebo

Trial Locations (1)

35043

Novartis Investigative Site, Marburg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY